Bayer Contemplates Breakup Amidst Poor Performance and Job Cuts
Bayer plans to overhaul its business structure and reduce management layers in response to declining performance, with CEO Bill Anderson stating that zero cash flow despite nearly €50 billion in revenue is unacceptable. While the company's Q3 pharmaceutical sales remained steady at €4.53 billion, its share price has dropped by 20% since last year.